Organization
PrECOG
6 clinical trials
Clinical trial
DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised TrialStatus: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
Phase II Study of Venetoclax (ABT-199/GDC-0199) in Combination With Obinutuzumab and Bendamustine in Patients With High Tumor Burden Follicular Lymphoma as Front Line TherapyStatus: Completed, Estimated PCD: 2021-05-03
Clinical trial
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)Status: Active (not recruiting), Estimated PCD: 2023-10-17
Clinical trial
A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell LymphomaStatus: Completed, Estimated PCD: 2022-09-22
Clinical trial
Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of AgeStatus: Active (not recruiting), Estimated PCD: 2022-10-20
Clinical trial
Open Label, Phase II Study of Anti - Programmed Death - Ligand 1 Antibody, Durvalumab (MEDI4736), in Combination With Chemotherapy for the First-Line Treatment of Unresectable MesotheliomaStatus: Completed, Estimated PCD: 2020-02-16